Improved additional efficacy outcomes in patients with 1L GC/GEJC and PD-L1 scores ≥1% vs placebo + chemotherapy1,2
Additional Efficacy Outcomes: PFS, ORR, and DCR with PD-L1 ≥1%
Improved response rates
- Nearly half of patients responded to TEVIMBRA + chemotherapy: 48% ORR (95% CI: 43%-53%) vs 41% ORR with placebo + chemotherapy (95% CI: 37%-46%)
- Nearly 90% DCR with TEVIMBRA + chemotherapy at 89.6% (95% CI: 86.3%-92.3%) vs 82.3% DCR with placebo + chemotherapy (95% CI: 78.5%-85.7%)
Efficacy analyses were descriptive only.
1L, first line; CPS, combined positive score; DCR, disease control rate; GC, gastric cancer; GEJC, gastroesophageal junction cancer; HR, hazard ratio; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival.
References: 1. TEVIMBRA. Prescribing Information. San Mateo, CA: Beigene, Ltd.; 2025.
2. Moehler M, Oh DY, Kato K, et al. Adv Ther. 2025;42(5):2248-2268. doi:10.1007/s12325-025-03133-7.